The varicella vaccine. Vaccine development.
In this article, rationales and method of development of attenuated live varicella (Oka) vaccine are described, with biologic and biophysical characteristics of the vaccine virus. The results of early clinical trials in Japan are also described, along with the results of detection of viremia in vaccinees and a follow-up of incidence of zoster in acute leukemic children, which indicate possible immunopathogenesis of varicella and zoster.
Takahashi
M
M
Research Institute for Microbial Diseases, Osaka University, Japan.
D002644:Chickenpox / Q000517:prevention & control / Q000821:virology; D019433:Chickenpox Vaccine / Q000235:genetics / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000517:prevention & control; D004279:DNA, Viral / Q000235:genetics; D006562:Herpes Zoster / Q000517:prevention & control / Q000821:virology; D014645:Herpesvirus 3, Human / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000821:virology; D012882:Skin Tests; D014613:Vaccines, Attenuated
D019433:Chickenpox Vaccine; D004279:DNA, Viral; D014613:Vaccines, Attenuated